The Weight-Loss Shots Semaglutide and Tirzepatide: Controversy and Understanding their Use
Échec de l'ajout au panier.
Veuillez réessayer plus tard
Échec de l'ajout à la liste d'envies.
Veuillez réessayer plus tard
Échec de la suppression de la liste d’envies.
Veuillez réessayer plus tard
Échec du suivi du balado
Ne plus suivre le balado a échoué
The Weight-Loss Shots Semaglutide and Tirzepatide: Controversy and Understanding their Use
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
This presentation is on the medications semaglutide and tirzepatide , prescribed under brand names such as Ozempic, Wegovy and Monjaro, and others, some of which are in development. These drugs are GLP-1 agonist medications most commonly used for the treatment of type 2 diabetes, but more recently it’s been in the spotlight as a medication for weight loss, causing controversy, misunderstanding, questions and significant shortages of the medication.
Dr. DeSarbo will briefly look at these medications from all perspectives including their use in diabetes, as a weight loss drug for the medical definition of obesity, and their potential impact and fallout with the eating disorder population.
Ce que les auditeurs disent de The Weight-Loss Shots Semaglutide and Tirzepatide: Controversy and Understanding their Use
Moyenne des évaluations de clientsÉvaluations – Cliquez sur les onglets pour changer la source des évaluations.
Il n'y a pas encore de critiques pour ce titre.